Across TCGA pan-cancer cohorts, HSD17B8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSD17B8 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HSD17B8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HSD17B8 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where HSD17B8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.916	0.755	.003	16	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.913	.045	12	view →
LUAD	OS	Median	All	0.911	0.975	.029	2	view →
HNSC	DFS	Median	II,III,IV	0.923	0.966	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: HSD17B8 tumor-vs-normal RNA expression · all HSD17B8 data types